The company shows strong growth across product lines, increased revenue guidance, and improved EBITDA margins. The Q&A reveals excitement around On-X's unique clinical data and AMDS's strong demand. Although management avoided specific 2026 guidance, the positive outlook for product launches and market expansions supports a positive sentiment. With a market cap of approximately $1 billion, the stock is likely to react positively, with a predicted movement of 2% to 8%.